{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:17:01Z","timestamp":1788322621127,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.jiac.2022.10.019","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T20:07:28Z","timestamp":1668024448000},"page":"193-197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy of sulfasalazine for the prevention of Pneumocystis pneumonia in patients with rheumatoid arthritis: A multicentric self-controlled case series study"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4484-0143","authenticated-orcid":false,"given":"Takahiro","family":"Nunokawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naofumi","family":"Chinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2860-4266","authenticated-orcid":false,"given":"Kota","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutsuto","family":"Tateishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keigo","family":"Setoguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Sugihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2022.10.019_bib1","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/1529-0131(199904)42:4<780::AID-ANR23>3.0.CO;2-M","article-title":"Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality","volume":"42","author":"Ward","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jiac.2022.10.019_bib2","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1007\/s10067-021-05660-4","article-title":"Pneumocystis jirovecii pneumonia in autoimmune rheumatic diseases: a nationwide population-based study","volume":"40","author":"Hsu","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jiac.2022.10.019_bib3","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3109\/s10165-005-0395-9","article-title":"Clinical characteristics of Pneumocystis carinii pneumonia in patients with connective tissue diseases","volume":"15","author":"Sato","year":"2005","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.jiac.2022.10.019_bib4","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.semarthrit.2015.01.007","article-title":"Pneumocystis jirovecci pneumonia in connective tissue diseases: comparison with other immunocompromised patients","volume":"45","author":"Teichtahl","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jiac.2022.10.019_bib5","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1164\/ajrccm.150.1.8025760","article-title":"Opportunistic infection during treatment with low dose methotrexate","volume":"150","author":"LeMense","year":"1994","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jiac.2022.10.019_bib6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3109\/03009749409102137","article-title":"Pneumocystis carinii pneumonia associated with low dose methotrexate treatment for rheumatoid arthritis","volume":"23","author":"Stenger","year":"1994","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.jiac.2022.10.019_bib7","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s10620-006-9250-x","article-title":"Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases","volume":"52","author":"Kaur","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jiac.2022.10.019_bib8","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1136\/ard.2011.151092","article-title":"Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients","volume":"70","author":"Koike","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jiac.2022.10.019_bib9","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3109\/s10165-010-0406-3","article-title":"Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis","volume":"21","author":"Koike","year":"2011","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.jiac.2022.10.019_bib10","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3109\/s10165-011-0541-5","article-title":"Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients","volume":"22","author":"Koike","year":"2012","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.jiac.2022.10.019_bib11","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/ard.2007.072967","article-title":"Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis","volume":"67","author":"Takeuchi","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jiac.2022.10.019_bib12","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1093\/rheumatology\/kes244","article-title":"Pneumocystis jirovecii infection: an emerging threat to patients with rheumatoid arthritis","volume":"51","author":"Mori","year":"2012","journal-title":"Rheumatology"},{"key":"10.1016\/j.jiac.2022.10.019_bib13","first-page":"101","volume":"vol. 16","author":"Lesch","year":"1997"},{"key":"10.1016\/j.jiac.2022.10.019_bib14","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1371\/journal.ppat.1001058","article-title":"Immune modulation with sulfasalazine attenuates immunopathogenesis but enhances macrophage- mediated fungal clearance during Pneumocystis pneumonia","volume":"6","author":"Wang","year":"2010","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jiac.2022.10.019_bib15","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.semarthrit.2018.05.013","article-title":"Prophylactic effect of sulfasalazine against Pneumocystis pneumonia in patients with rheumatoid arthritis: a nested case-control study","volume":"48","author":"Nunokawa","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jiac.2022.10.019_bib16","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1080\/14397595.2018.1465647","article-title":"Effect of sulfasalazine use on the presence of Pneumocystis organisms in the lung among patients with rheumatoid arthritis: a test-negative design case-control study with PCR tests","volume":"29","author":"Nunokawa","year":"2019","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.jiac.2022.10.019_bib17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ajic.2018.06.016","article-title":"Antibiotic exposure and risk of community-associated Clostridium difficile infection: a self-controlled case series analysis","volume":"47","author":"Didiodato","year":"2019","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.jiac.2022.10.019_bib18","doi-asserted-by":"crossref","first-page":"i4515","DOI":"10.1136\/bmj.i4515","article-title":"Self controlled case series methods: an alternative to standard epidemiological study designs","volume":"354","author":"Petersen","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.jiac.2022.10.019_bib19","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1002\/sim.2302","article-title":"Tutorial in biostatistics: the self-controlled case series method","volume":"25","author":"Whitaker","year":"2006","journal-title":"Stat Med"},{"key":"10.1016\/j.jiac.2022.10.019_bib20","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/art.24283","article-title":"Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients","volume":"61","author":"Komano","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jiac.2022.10.019_bib21","doi-asserted-by":"crossref","first-page":"915","DOI":"10.2169\/internalmedicine.47.0702","article-title":"Clinical and radiological features of Pneumocystis pneumonia in patients with rheumatoid arthritis, in comparison with methotrexate pneumonitis and Pneumocystis pneumonia in acquired immunodeficiency syndrome: a multicenter study","volume":"47","author":"Tokuda","year":"2008","journal-title":"Inter Med"},{"key":"10.1016\/j.jiac.2022.10.019_bib22","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/RHU.0000000000000731","article-title":"Risk factors for pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis and a prophylactic indication of trimethoprim\/sulfamethoxazole","volume":"24","author":"Yukawa","year":"2018","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.jiac.2022.10.019_bib23","series-title":"Self-controlled case series studies","first-page":"47","article-title":"The standard SCCS model","author":"Farrington","year":"2018"},{"key":"10.1016\/j.jiac.2022.10.019_bib24","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1111\/imj.12599","article-title":"Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies","volume":"44","author":"Cooley","year":"2014","journal-title":"Intern Med J"},{"key":"10.1016\/j.jiac.2022.10.019_bib25","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1001\/archinte.1996.00440020081010","article-title":"A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens","volume":"156","author":"Ioannidis","year":"1996","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jiac.2022.10.019_bib26","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/annrheumdis-2017-211796","article-title":"Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids","volume":"77","author":"Park","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jiac.2022.10.019_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-019-1996-6","article-title":"Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids - clinical implication of primary prophylaxis using trimethoprim-sulfamethoxazole","volume":"21","author":"Park","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jiac.2022.10.019_bib28","first-page":"671","article-title":"Pneumocystis jiroveci pneumonia in rheumatic disease: a 20-year single-centre experience","volume":"35","author":"Mecoli","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jiac.2022.10.019_bib29","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1016\/j.chest.2020.05.558","article-title":"Risk factors and prevention of Pneumocystis jirovecii pneumonia in patients with autoimmune and inflammatory diseases","volume":"158","author":"Ghembaza","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.jiac.2022.10.019_bib30","first-page":"CD005590","article-title":"Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients","author":"Stern","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jiac.2022.10.019_bib31","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.4065\/82.9.1052","article-title":"Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials","volume":"82","author":"Green","year":"2007","journal-title":"Mayo Clinic"},{"key":"10.1016\/j.jiac.2022.10.019_bib32","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.semarthrit.2011.05.004","article-title":"Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients with connective tissue diseases","volume":"41","author":"Vananuvat","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jiac.2022.10.019_bib33","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2169\/internalmedicine.50.4508","article-title":"Clinical and radiological features of acute-onset diffuse interstitial lung diseases in patients with rheumatoid arthritis receiving treatment with biological agents: importance of Pneumocystis pneumonia in Japan revealed by a multicenter study","volume":"50","author":"Kameda","year":"2011","journal-title":"Inter Med"},{"key":"10.1016\/j.jiac.2022.10.019_bib34","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1164\/ajrccm\/140.5.1204","article-title":"Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS","volume":"140","author":"Limper","year":"1989","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.jiac.2022.10.019_bib35","doi-asserted-by":"crossref","first-page":"R43","DOI":"10.1186\/ar4472","article-title":"The prophylaxis for Pneumocystis pneumonia in patients with rheumatoid arthritis treated with biologics, based on risk factors found in a retrospective study","volume":"16","author":"Katsuyama","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jiac.2022.10.019_bib36","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11046-012-9579-y","article-title":"Detection of (1, 3)-\u03b2-d-glucan in bronchoalveolar lavage and serum samples collected from immunocompromised hosts","volume":"175","author":"Theel","year":"2013","journal-title":"Mycopathologia"},{"key":"10.1016\/j.jiac.2022.10.019_bib37","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.cmi.2020.05.024","article-title":"Diagnostic accuracy of serum (1-3)-\u03b2-D-glucan for Pneumocystis jirovecii pneumonia: a systematic review and meta-analysis","volume":"26","author":"Del Corpo","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jiac.2022.10.019_bib38","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.1002\/art.27735","article-title":"Trends in hospitalizations for Pneumocystis jiroveci pneumonia among patients with rheumatoid arthritis in the US: 1996-2007","volume":"62","author":"Louie","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jiac.2022.10.019_bib39","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1093\/rheumatology\/kew200","article-title":"Risk of Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis treated with inhibitors of tumour necrosis factor \u03b1: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis","volume":"55","author":"Bruce","year":"2016","journal-title":"Rheumatology"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X22003026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X22003026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:05:37Z","timestamp":1761159937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X22003026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S1341321X22003026"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2022.10.019","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of sulfasalazine for the prevention of Pneumocystis pneumonia in patients with rheumatoid arthritis: A multicentric self-controlled case series study","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2022.10.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}